Showing 1781-1790 of 9336 results for "".
- Almirall and University of Michigan Collaborate to Gain Understanding of Disease Drivers in Hidradenitis Suppurativahttps://practicaldermatology.com/news/almirall-and-university-of-michigan-collaborate-to-gain-understanding-of-disease-drivers-in-hidradenitis-suppurativa/2461107/Almirall, S.A. entered into a collaboration agreement with the University of Michigan to accelerate the understanding of the factors that trigger hidradenitis suppurativa. Through this partnership, Almirall's expertise in skin diseases will be combined with the knowledge of the Dermatology Departme…
- PCA SKIN® Recognizes Third Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-recognizes-third-annual-national-peel-day/2461104/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities. National Peel Day is recognized by National Day Archiv…
- Dermatologists Can Support Medical, Humanitarian Efforts in Ukrainehttps://practicaldermatology.com/news/how-to-help-ukraine/2461103/Many Americans feel hopeless as they watch images of displaced Ukrainian citizens fleeing their country due to ongoing Russian attacks. EADV President Professor Alexander Stratigos and Secretary General Professor Carmen Salavastru have issued a statement of solidarity with "our fellow dermatologist…
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of variation …
- Mblue Labs Introduces First Anti-Aging, Coral Safe Sunscreen with Methylene Bluehttps://practicaldermatology.com/news/mblue-labs-introduces-first-anti-aging-coral-safe-sunscreen-with-methylene-blue/2461094/Mblue Labs is launching Bluevado SunFix, the first sunscreen with Methylene Blue, a centuryold medicine that is also safe for coral reefs and also delays skin aging. Fully 80 percent of today’s sunscreens use Oxybenzone as a chemical UV blocker, despite studies that have shown it expedites the des…
- Cetaphil Sensitive Skin Awareness Month Kicks off on March 1, 2022https://practicaldermatology.com/news/cetaphil-sensitive-skin-awareness-month-kicks-off-on-march-1-2022/2461093/Cetaphil is extending Sensitive Skin Awareness Week to a month-long program. Cetaphil is debuting Sensitive Skin Awareness Month this March. In partnership with expert dermatologists and influencers – dubbed the Sensitive Skin Academy – Cetaphil is extending last year’s Sensitive Skin Week into a …
- US Senate Passes Dr. Lorna Breen Acthttps://practicaldermatology.com/news/us-senate-passes-lorna-breen-act/2461090/The US Senate has passed the bipartisan Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667). The bill previously was passed by the US House of Representatives, and now goes to President Biden to be signed into law. Once signed, the Dr. Lorna Breen Health Care Provider Protection Act w…
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data also suggests a favo…
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulat…
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not be…